Shots:

• The P-III REGN-COV 2069 trial involves assessing the efficacy and safety of Ab cocktail (casirivimab (1200 mg- SC) + imdevimab (1200 mg- SC) vs PBO in 1-505 people to prevent symptomatic infection in household contacts of individuals infected with COVID-19
• The trial met its 1EP and 2EPs showed an 81% reduction in the risk of symptomatic infections- patients with symptomatic infection resolved symptoms (1 vs 3wk.). In a cohort of infected asymptomatic patients- Ab cocktail showed a 31% reduction in the overall risk of progressing to symptomatic COVID-19
• The companies will share the results with regulatory authorities including the EMA and the FDA

  Ref: GlobeNewswire | Image: Roche